We are pleased to announce the launch of the brand new ODYSSEY website!
Included among the various features on the site are a background of the study, the objectives set, treatment overview with news updates, and a link to the reserved area on the PENTA website. It has been carefully designed with a vibrant user-friendly interface that, with the addition of a contact form, we hope will foster continued communication between us and anyone interested in ODYSSEY. The website content will be periodically updated with easy-to access information, news, and articles related to the clinical trial.
ODYSSEY is a multi-centre, randomised clinical trial to assess the efficacy and toxicity of Dolutegravir plus 2 NRTI versus standard of care among HIV positive children and adolescents. PENTA is sponsor of this study, with 700 patients to be enrolled in 30 sites in Europe, the US, Latin America, Africa and Asia.
This study includes a pharmacokinetics substudy in children 2 to 6 years of age, and results will be used to support regulatory submission for marketing of Dolutegravir in this population.
The website can be found at: www.odysseytrial.org